Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 11/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CTRC | Q99895 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1882301 | 0.91 | MEN1 (0.49) | CMA1MEN1KMT2AELANENPC1 | |
| SCHEMBL8691338 | 0.88 | ELANE (0.46) | MEN1KMT2AELANE | |
| SCHEMBL5850980 | 0.85 | FKBP4 (0.48) | CMA1MEN1KMT2ACTRC | |
| SCHEMBL3396899 | 0.85 | ELANE (0.48) | ELANE | |
| SCHEMBL3244930 | 0.84 | ELANE (0.43) | CMA1MEN1KMT2AELANE | |
| SCHEMBL29888704 | 0.84 | FKBP4 (0.44) | CMA1ELANE | |
| SCHEMBL9699194 | 0.83 | CMA1 (0.67) | CMA1ELANECTRC | |
| SCHEMBL31031631 | 0.83 | FKBP4 (0.44) | CMA1ELANE | |
| SCHEMBL29463298 | 0.83 | FKBP4 (0.49) | CMA1ELANE | |
| SCHEMBL29558027 | 0.82 | FKBP4 (0.55) | CMA1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283344-B2 | Method of treating inherited severe neutropenia | MERCK & CO., INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20110059960-A1 | METHOD OF TREATING INHERITED SEVERE NEUTROPENIA | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| EP-0595557-B1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO INC (US) | 2004-06-30 | — | — | EP | disclosed |
| US-5952321-A | Substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO., INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5747485-A | RESPIRATORY SYSTEM DISORDERS | MERCK & CO., INC. (US) | 1998-05-05 | — | — | US | disclosed |
| US-5591737-A | ELASTASE INHIBITORS | MERCK & CO., INC. (US) | 1997-01-07 | — | — | US | disclosed |
| EP-0337549-B1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO INC (US) | 1995-10-04 | — | — | EP | disclosed |
| US-5348953-A | Elastase inhibitor | MERCK & CO., INC. (US) | 1994-09-20 | — | — | US | disclosed |
| WO-1994010143-A1 | NEW SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0595557-A1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1994-05-04 | — | — | EP | disclosed |
| US-5229381-A | Inhibitors of leukocyte enzyme elastase | MERCK & CO., INC. (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0525973-A2 | Substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| EP-0505095-A2 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1992-09-23 | — | — | EP | disclosed |
| EP-0505097-A2 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1992-09-23 | — | — | EP | disclosed |
| EP-0481671-A1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1992-04-22 | — | — | EP | disclosed |
| US-5104862-A | Bethalactam elastase inhibitors containing phosphorous acid derivatives at the 4-position of the 2-azetidinone | MERCK & CO., INC. (US) | 1992-04-14 | — | — | US | disclosed |
| US-5100880-A | Treatment of rheumatoid arthritis and emphysema, enzyme inhibitors | MERCK & CO., INC. (US) | 1992-03-31 | — | — | US | disclosed |
| EP-0337549-A1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059960-A1 | METHOD OF TREATING INHERITED SEVERE NEUTROPENIA | SCN1B, SCNN1B, SCNN1A | CMA1 1179/4885MEN1 832/4885KMT2A 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.